



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 29 July 2022

In compliance with the information duties provided for in article 227 of the restated text of the Securities Market Act, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Market Commission the following

OTHER RELEVANT INFORMATION

Following the communication of other relevant information number 16,848, dated 16 June 2022, it is hereby informed that the public deed relating to the share capital decrease in the amount of EUR 123,168.48, through the amortisation of 2,052,808 treasury shares, was registered with the Commercial Registry of Madrid and the shares have been delisted with effect on 29 July 2022 on the Stock-Exchange Interconnection System (*Sistema de Interconexión Bursátil*) and on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges.

As a result, the share capital of the Company has been set at EUR 3,240,969.42, divided into 54,016,157 ordinary shares, with a nominal value of EUR 0.06 each, which



grant a total of 54,016,157 voting rights (one per share). By amortizing these shares, the shareholders automatically increase their percentage interest in the capital stock.

The share capital reduction was approved by the Ordinary General Shareholders' Meeting of the Company held on 14 June 2022, under item Eight of its agenda.

As a result of this operation, article 5 of ROVI' bylaws has been amended to read as follows:

"Article 5.- Share capital and shares

The share capital is 3,240,969.42 euros. It is divided into 54,016,157 ordinary shares with a par value of 0.06 euros each, belonging to a single class and series. All the share fully subscribed and paid, and all grant their holders the same political and economic rights."

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer (*Consejero Delegado*)

Laboratorios Farmacéuticos ROVI, S.A.